Tourmaline Bio Inc (NASDAQ: TRML) on Tuesday, plunged -7.47% from the previous trading day, before settling in for the closing price of $13.92. Within the past 52 weeks, TRML’s price has moved between $12.12 and $48.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 67.15%. With a float of $15.60 million, this company’s outstanding shares have now reached $25.64 million.
In an organization with 52 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 49.12%, operating margin of -2628.43%, and the pretax margin is -2146.27%.
Tourmaline Bio Inc (TRML) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tourmaline Bio Inc is 39.16%, while institutional ownership is 63.88%. The most recent insider transaction that took place on Aug 21 ’24, was worth 26,418. In this transaction CEO of this company bought 1,779 shares at a rate of $14.85, taking the stock ownership to the 7,000 shares. Before that another transaction happened on Aug 16 ’24, when Company’s CEO bought 5,221 for $13.79, making the entire transaction worth $71,998. This insider now owns 5,221 shares in total.
Tourmaline Bio Inc (TRML) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 67.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.01% during the next five years compared to -19.23% drop over the previous five years of trading.
Tourmaline Bio Inc (NASDAQ: TRML) Trading Performance Indicators
Tourmaline Bio Inc (TRML) is currently performing well based on its current performance indicators. A quick ratio of 40.33 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -3.53 in one year’s time.
Technical Analysis of Tourmaline Bio Inc (TRML)
Let’s dig in a bit further. During the last 5-days, its volume was 0.54 million. That was better than the volume of 0.31 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 5.45%. Additionally, its Average True Range was 1.03.
During the past 100 days, Tourmaline Bio Inc’s (TRML) raw stochastic average was set at 0.73%, which indicates a significant decrease from 2.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.23% in the past 14 days, which was lower than the 61.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.98, while its 200-day Moving Average is $19.09. However, in the short run, Tourmaline Bio Inc’s stock first resistance to watch stands at $13.51. Second resistance stands at $14.14. The third major resistance level sits at $14.51. If the price goes on to break the first support level at $12.50, it is likely to go to the next support level at $12.13. The third support level lies at $11.50 if the price breaches the second support level.
Tourmaline Bio Inc (NASDAQ: TRML) Key Stats
Market capitalization of the company is 330.28 million based on 25,643K outstanding shares. Right now, sales total 0 K and income totals -42,120 K. The company made 0 K in profit during its latest quarter, and -20,180 K in sales during its previous quarter.
